Search

Displaying results 2101 - 2110 of 4590 in total
  1. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indicati...

  2. Drug

    Chlorquinaldol

    go.drugbank.com/drugs/DB13306
    Approved

    Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]

  3. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    Romosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921]. Romosozumab was granted FDA approval on April 9,2019[L5921]. … In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months

  4. Drug

    Enfuvirtide

    go.drugbank.com/drugs/DB00109
    ApprovedInvestigational

    The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.

  5. Drug

    Methylcellulose

    go.drugbank.com/drugs/DB11228
    ApprovedInvestigational

    Methyl cellulose is a hydrophilic white powder in pure form and dissolves in cold (but not in hot) water, forming a clear viscous solution or gel.

  6. Drug

    Bromotheophylline

    go.drugbank.com/drugs/DB14018
    Approved

    [L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113]

  7. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

  8. Drug

    Iopamidol

    go.drugbank.com/drugs/DB08947
    ApprovedInvestigational

    Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

  9. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940] By preventing this aberrant signaling, it reduces the formation of new abnormal bone.[L63940] It is administered by intravenous infusion every four weeks. … [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.

  10. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.